Abstract
In keeping with other immune-mediated inflammatory rheumatic diseases, treatment choices for axial spondyloarthritis (axSpA) have expanded beyond nonsteroidal antiinflammatory drugs (NSAIDs) and physical therapy in the last 20 years. We now have 10 advanced therapies from 3 distinct modes of action (ie, tumor necrosis factor inhibitors [TNFi], interleukin 17 inhibitors [IL-17i], and Janus kinase inhibitors [JAKi]), and novel modalities are being investigated.
